Advanced right ventricular failure 55Ħ.3.7.1. Balloon atrial septostomy and Potts shunt 54Ħ.3.7. Pulmonary arterial hypertension with cardiopulmonary comorbidities 53Ħ.3.6.1. Treatment decisions during follow-up in patients without cardiopulmonary comorbidities 52Ħ.3.4.3. Initial treatment decision in patients without cardiopulmonary comorbidities 51Ħ.3.4.2.
Treatment strategies for patients with idiopathic, heritable, drug-associated, or connective tissue disease-associated pulmonary arterial hypertension 50Ħ.3.4.1. Prostacyclin analogues and prostacyclin receptoragonists 50Ħ.3.4. Phosphodiesterase 5 inhibitors and guanylate cyclase stimulators 49Ħ.3.3.4. Endothelin receptor antagonists 47Ħ.3.3.3. Pulmonary arterial hypertension therapies 46Ħ.3.3.2. Physical activity and supervised rehabilitation 43Ħ.3.3. Comprehensive prognostic evaluation, risk assessment, and treatment goals 42Ħ.3.1.1. Patient-reported outcome measures 41Ħ.2.7. Cardiac magnetic resonance imaging 39Ħ.2.6. Pulmonary arterial hypertension (group 1) 38Ħ.2.2.2. Exercise right heart catheterization 30ĥ.1.13. Right heart catheterization, vasoreactivity, exercise, and fluid challenge 29ĥ.1.12.3. Cardiopulmonary exercise testing 29ĥ.1.12.
Cardiac magnetic resonance imaging 28ĥ.1.11. Non-contrast and contrast-enhanced chest computed tomography examinations, and digital subtraction angiography 27ĥ.1.8. Pulmonary function tests and arterial blood gases 24ĥ.1.6. Group 5, pulmonary hypertension with unclear and/or multifactorial mechanisms 23ĥ.1.4. Group 4, pulmonary hypertension associated with chronic pulmonary artery obstruction 23Ĥ.5. Group 3, pulmonary hypertension associated with lung diseases and/or hypoxia 23Ĥ.4. Group 2, pulmonary hypertension associated with left heart disease 23Ĥ.3. Group 1, pulmonary arterial hypertension 21Ĥ.2.
0 kommentar(er)
